RCUS
Arcus Biosciences, Inc.
NYSE · Healthcare · Biotechnology · US
$29.66
−1.56%Year over year
Reported trailing growth
- Revenue
- -55.3%
- EBITDA
- -48.6%
- EBIT
- -43.8%
- EPS
- -20.6%
- Free cash flow
- -38.9%
- Operating cash flow
- -39.8%
Forward estimates
Based on analyst estimates
- Revenue
- -69.4%
- EBITDA
- -5.2%
- EPS
- +3.4%
Three-year CAGR
- Revenue
- +30.2%
- EBITDA
- -24.5%
- EBIT
- -17.0%
- Net income
- -24.7%
- EPS
- -4.8%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026